| |
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of- the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:
Dr Burstein (interview conducted on July 8, 2005) — Speakers Bureau: Genentech BioOncology. Dr Vogel (interview conducted on July 8, 2005) — Grants/Research Support: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biomira Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, TAIHO Pharmaceutical Co Ltd; Honorarium and Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biomira Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Mamounas (interview conducted on February 26, 2005) — Consulting Fees: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Novartis Pharmaceuticals, Pfizer Inc, Sanofi-Aventis; Honoraria: AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Novartis Pharmaceuticals, Pfizer Inc, Sanofi-Aventis.
The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Terry Ann Glauser, MD, MPH, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — ownership interest in Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi- Aventis, who have no influence on the content development of our educational activities.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
|
|
